prikaz prve stranice dokumenta Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer
  Preuzmi
PDF 424.35 KB
Znanstveni rad - Izvorni znanstveni rad
Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer
Life, 14 (2024), 7; 789. https://doi.org/10.3390/life14070789
Bakula, Mirko; Hudolin, Tvrtko; Knežević, Nikola; Zimak, Zoran; Anđelić, Jerko; Jurić, Ilija; Gamulin, Marija; Gnjidić, Milena; Kaštelan, Željko

Citiranost:
,
Citirajte ovaj rad

Bakula, M., Hudolin, T., Knežević, N., Zimak, Z., Anđelić, J., Jurić, I. ... Kaštelan, Ž. (2024). Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer. Life, 14. (7). doi: 10.3390/life14070789

Bakula, Mirko, et al. "Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer." Life, vol. 14, br. 7, 2024. https://doi.org/10.3390/life14070789

Bakula, Mirko, Tvrtko Hudolin, Nikola Knežević, Zoran Zimak, Jerko Anđelić, Ilija Jurić, Marija Gamulin, Milena Gnjidić i Željko Kaštelan. "Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer." Life 14, br. 7 (2024). https://doi.org/10.3390/life14070789

Bakula, M., et al. (2024) 'Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer', Life, 14(7). doi: 10.3390/life14070789

Bakula M, Hudolin T, Knežević N, Zimak Z, Anđelić J, Jurić I, i sur.. Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer. Life [Internet]. 22.06.2024. [pristupljeno 24.04.2025.];14(7). doi: 10.3390/life14070789

M. Bakula, et al., "Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer", Life, vol. 14, br. 7, Lipanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:582855. [Citirano: 24.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:582855
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Intravesical Gemcitabine and Docetaxel Therapy for BCG-Naïve Patients: A Promising Approach to Non-Muscle Invasive Bladder Cancer
AutorMirko Bakula
AutorTvrtko Hudolin
AutorNikola Knežević
AutorZoran Zimak
AutorJerko Anđelić
AutorIlija Jurić
AutorMarija Gamulin
AutorMilena Gnjidić
AutorŽeljko Kaštelan
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA KLINIČKU ONKOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA UROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Urologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Bacillus Calmette-Guérin (BCG) therapy for patients with non-muscle invasive bladder cancer (NMIBC) faces limitations in efficacy and significant side effects, aggravated by a recent global shortage. In this prospective clinical study, we report the outcomes of sequential intravesical administration of gemcitabine and docetaxel (Gem/Doce) as a first-line treatment for BCG-naïve patients with high-risk NMIBC (HR NMIBC). From October 2019 until April 2022, we enrolled 52 patients and followed the... Više treatment protocol set forth by the University of Iowa. Follow-up assessments were conducted every 3 months. In this cohort, 25 (48.1%) patients were diagnosed with high-grade T1 (T1HG) bladder cancer, 10 (19.2%) patients had carcinoma in situ (CIS), and 17 (32.7%) patients had a combination of T1HG+CIS. The median time to first recurrence in the T1HG, CIS, and T1HG+CIS groups was 11, 10.5, and 8.8 months, respectively. The recurrence-free survival was 98.1%, 94.2%, and 80.8% at 6, 9, and 12 months, respectively. The rate of progression-free survival was 100%, 98.1%, and 92.3% at 6, 9, and 12 months, respectively. We demonstrated the safety and efficacy of Gem/Doce therapy in BCG-naïve patients with HR NMIBC during a one-year follow-up. Further research with extended follow-ups, as well as direct comparisons of Gem/Doce with other anticancer agents, is essential. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaLife
Brojčani podacivol. 14, br. 7, 789
e-ISSN2075-1729
DOIhttps://doi.org/10.3390/life14070789
URN:NBNurn:nbn:hr:105:582855
Datum objave publikacije2024-06-22
URL dokumentahttps://www.mdpi.com/2075-1729/14/7/789
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2025-04-03 07:04:36
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.